. "References to the base substances are therefore intended to include those common salts known to be substantially equivalent to the parent compound. [0026] The formulations as described above will be administered for a prolonged period, that is, for as long as the potential for cardiovascular events and disease including coronary artery disease and/or cerebrovascular disease remains or the symptoms" . . .